Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has identified G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative disease and arthritis.
University of Copenhagen has divulged 4-hydroxypyridine and 4-hydroxyquinoline derivatives acting as G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of fibrosis, diabetes, inflammatory and cognitive disorders.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Bayer AG has synthesized new furoindazole derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of inflammation, metabolic disorders, autoimmune and lung diseases, among others.
